45. Karp, S.E., Hwu, P., Farber, A., Restifo, N.P., Kriegler, M., Mule, J.J., 
and Rosenberg, S.A. Secretory but not membrane-bound TNF mediates the 
regression of retrovirally transduced murine tumor. J. Immunol. 149: 2076-2081, 
1992. 
46. Colombo, M.P., Modesti, A., Parmiani, G., and Forni, G. Local cytokine 
availability elicits tumor rejection and systemic immunity. Cancer Res. 52: 
4853-4857, 1992. 
47. Mullen, C.A., Coale, M.M., Levy, A.T., Stetler-Stevenson, W.G., Liotta, 
L . A . Brandt, S. and Blaese, R.M. Fibrosarcoma cells transduced with the IL-6 
gene exhibit reduced tumorigenicity , increased immunogenicity , and decreased 
metastatic potential. Cancer Res. 52: 6020-6024, 1992. 
48. Watanabe, Y., Kuribayashi, K., Mitatake, S., Nishihara, K., Nakayama, E., 
Tanayoshi, T. and Sakata, T. Exogenous expression of mouse interferon-r cDNA 
in mouse neuroblastoma C1300 cells results in decreased tumorigenicity by 
augmented anti-tumor immunity. Proc. Nat. Acad. Sci. (USA) 86: 9456-9460, 1989. 
49. Asher, A. I., Mule, J.J., Restifo, N.P., Salo, J.C., Reichert, C.M., Jaffe, 
G., Fendly, B., Kriegler, M. and Rosenberg, S.A. Murine tumor cells transduced 
with the gene for tumor necrosis factor. J. Immunol 146: 3227-3234,1991. 
50. Sun, W.H., Kreisle, R.A., Phillips, A.W. and Ershler, W.B. In vivo and in 
vitro characteristics of interleukin-6-transfected B16 melanoma cells. Cancer 
Res . 52: 5412-5415, 1992. 
51. Gansbacher, B., Zier, K., Daniels, K.C., Banner ji R. and Gilboa, E. 
Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and 
induces protective immunity. J. Exp. Med. 172: 1217-1224, 1990 
52. Prehn, R.T. and Main, J. Immunity to methylcholanthrene-induced sarcomas. 
J. Nat. Can. Inst . 18: 769-794, 1957 
53. Eberlein, T., Rosenstein, M. and Rosenberg, S.A. Regression of a 
disseminated syngeneic solid tumor by systemic transfer of lymphoid cells 
expanded in interleukin-2. J. Exp. Med . 156: 85-94, 1982. 
54. Papa, M.Z., Mule, J.J., and Rosenberg, S.A. Antitumor efficacy of 
lymphokine-activated killer cells and recombinant interleukin 2 in vivo: 
Successful immunotherapy of established pulmonary metastases from weakly 
immunogenic and nonimmunogenic murine tumors of three distinct histological 
types. Cancer Res. 46: 4973-4978, 1986. 
55. Rosenberg, S.A., Spiess, P., and Lafreniere, R. A new approach to the 
adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 
233:1318-1321, 1986. 
56. Topalian, S.L., Solomon, D., and Rosenberg, S.A. Tumor-specific cytolysis 
by lymphocytes infiltrating human melanomas. J . Immunol . 142: 3714-3725, 1989. 
57. Cheever, M.A., Greenberg, P.D., Fefer, A. and Gillis, S. Augmentation of 
the anti tumor therapeutic efficacy of long-term cultured T lymphocytes by in 
vivo administration of purified interleukin-2. J. Exp. Med. 155: 968-974, 1982. 
58. Berd, D., Maguire, H.C. Jr., and Mastrangelo, M.J. Induction of cell- 
mediated immunity to autologous melanoma cells and regression of metastases 
Recombinant DNA Research, Volume 18 
[363] 
